📌TL;DR
- •Non-GLP-1 mechanism targeting amylin and calcitonin receptors
- •7.77% weight loss in just 43 days (phase 1 MAD interim data)
- •Long half-life (11 days) enabling once-weekly dosing
- •Potential for combination with GLP-1 RAs for enhanced efficacy
Community-Reported Side EffectsAnecdotal?
Protocol Quick-Reference
Obesity (weight management)
Dosing
Amount
2 mg (phase 1 MAD dose showing efficacy)
Frequency
Once weekly
Duration
Ongoing (6 weeks evaluated in phase 1)
Step-wise Titration (4 weeks)
Administration
Route
SCSchedule
Once weekly
Timing
Weekly subcutaneous injection
✓ Rotate injection sites
Cycle
Duration
Ongoing
Repeatable
Yes
Preparation & Storage
✓ Ready-to-use — no reconstitution required
Storage: Likely refrigerated (2-8 degrees C). Consult clinical trial protocol.
💡 Key Considerations
- →Early-stage investigational drug (phase 1 only)
- →Only available through clinical trials
- →Dose escalation likely required based on class experience
- →Phase 2 dosing may differ from phase 1
Subscribe to unlock this content
Get weekly peptide research summaries, new study alerts, and protocol updates — free.
150+ peptide profiles · 30+ comparisons · 18 research tools
Scientific Details
- Molecular Formula
- Proprietary (not publicly disclosed)
- Molecular Weight
- 4000 Da
- Sequence
- Proprietary long-acting amylin analog (not publicly disclosed)
What is GUBamy?#
GUBamy (GUB014295) is a novel long-acting peptide that acts as a dual amylin and calcitonin receptor agonist (DACRA), developed by Gubra, a Danish biotechnology company specializing in peptide-based therapeutics for metabolic diseases. The drug represents a mechanistically distinct approach to obesity treatment compared to the dominant GLP-1 receptor agonist class.
In March 2025, AbbVie entered the obesity market by licensing GUBamy from Gubra in a deal worth $350 million upfront plus potential milestones, signaling significant pharmaceutical industry interest in non-GLP-1 obesity mechanisms.
Mechanism of Action#
GUBamy acts through dual activation of amylin and calcitonin receptors:
Amylin Receptor Agonism#
Amylin (islet amyloid polypeptide, IAPP) is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells. Its physiological effects include:
- Appetite suppression: Acts on the area postrema in the brainstem to reduce food intake
- Gastric emptying delay: Slows gastric motility, contributing to satiety
- Glucagon suppression: Reduces postprandial glucagon secretion
- Postprandial glucose regulation: Complements insulin in glucose homeostasis
The only approved amylin analog, pramlintide (Symlin), has a short half-life requiring thrice-daily injection, limiting its practical utility. GUBamy's long-acting design (11-day half-life) overcomes this limitation.
Calcitonin Receptor Agonism#
Calcitonin receptors mediate additional metabolic effects:
- Energy expenditure: Calcitonin receptor signaling may increase energy expenditure
- Appetite regulation: Additional brainstem appetite suppression pathways
- Bone metabolism: Calcitonin naturally inhibits osteoclast activity (though the metabolic relevance in obesity treatment is unclear)
Complementary to GLP-1#
The amylin/calcitonin receptor pathway is mechanistically distinct from GLP-1 signaling:
- Different receptor targets (AMY1-3 and CTR vs GLP-1R)
- Different neuroanatomical sites of action (brainstem area postrema vs hypothalamus)
- Non-overlapping signaling cascades
- Preclinical evidence suggests additive or synergistic weight loss when combined with GLP-1 RAs
Clinical Development#
GUBamy is in early clinical development:
- Phase 1 SAD (Single Ascending Dose): Completed; demonstrated safety, dose proportionality, and dose-dependent weight loss
- Phase 1 MAD (Multiple Ascending Dose): Interim results showed 7.77% weight loss at 2 mg weekly by day 43
- AbbVie partnership: $350M upfront payment for worldwide development rights (March 2025)
- Next steps: Phase 2 trials expected under AbbVie's development
Important Considerations#
GUBamy is an early-stage investigational medication with only phase 1 data available. Key considerations include:
- Very limited clinical data (phase 1 only)
- Long-term safety and efficacy are completely unknown
- The phase 1 weight loss results, while impressive for the stage, need confirmation in larger, longer trials
- Combination therapy potential with GLP-1 RAs is theoretical and untested in clinical trials
- The 11-day half-life is advantageous for weekly dosing but means prolonged drug exposure if adverse events occur
Key Research Findings#
Gubra Announces Positive GUBamy Phase 1 SAD Data, published in Company press release (Gubra A/S, 2024):
- The study showed half life of 270 hours confirmed
- The study demonstrated weight loss of 3% in highest dose groups over 6 weeks
Gubra Announces Positive GUBamy Phase 1 Interim MAD Results, published in Company press release (Gubra A/S, 2024):
- The study showed LS mean weight loss of 7.77% at day 43 with GUBamy 2 mg weekly
- The study showed weight change at day 43 of 1.99%
Related Reading#
Stay current on GUBamy research
We summarize new studies, safety updates, and dosing insights — delivered biweekly.
Community Protocols Available
See real-world usage patterns alongside the clinical evidence above. Community-sourced, not clinically verified.
0View community protocolsFrequently Asked Questions About GUBamy
What is GUBamy?
GUBamy (GUB014295) is a long-acting peptide that activates both amylin receptors (AMY1-3) and calcitonin receptors (CTR). This dual receptor agonism (DACRA) suppresses appetite through brainstem signaling pathways that are complementary to GLP-1-based mechanisms. It is being developed by Gubra, a Danish biotechnology company, with AbbVie as the licensee for global development.
How is GUBamy different from GLP-1 drugs?
GUBamy works through a fundamentally different mechanism than GLP-1 receptor agonists like semaglutide. While GLP-1 RAs act primarily through hypothalamic satiety centers and incretin effects, GUBamy targets amylin and calcitonin receptors in the area postrema and other brainstem regions. This non-overlapping mechanism makes it a candidate for combination therapy with GLP-1 RAs.
What clinical results has GUBamy shown?
Phase 1 SAD data showed dose-dependent weight loss of approximately 3% in the highest dose groups after a single dose. Phase 1 MAD interim data showed 7.77% mean weight loss at the 2 mg weekly dose by day 43, compared to 1.99% weight gain with placebo.
What is the AbbVie deal?
In March 2025, AbbVie and Gubra announced a worldwide license agreement for GUBamy. AbbVie paid $350 million upfront, with additional milestone payments possible, to develop GUBamy for the treatment of obesity.
Explore Further
Related Peptides
View all peptides →Pramlintide (Symlin)
Pramlintide (Symlin): FDA-approved synthetic amylin analog for type 1 and type 2 diabetes. Adjunct to mealtime insulin for postprandial glucose control with weight loss benefit.
Cagrilintide
Cagrilintide: Long-acting amylin analog for obesity. Covers satiety mechanism, CagriSema combination data, Phase 3 results, dosing, and side effects.
Amycretin
Amycretin: Novo Nordisk unimolecular GLP-1/amylin receptor agonist. Phase 1b/2a showed up to 24.3% weight loss at 36 weeks. SC and oral formulations. Phase 3 planned.
Petrelintide
Petrelintide (ZP8396): long-acting amylin analog by Zealand Pharma, licensed to Roche for $5.3B. Phase 1b showed 8.6% weight loss. Phase 2b ZUPREME underway.
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.
You Might Also Like
Related content you may find interesting